According to a recent LinkedIn post from Francis Medical, the company is highlighting what it describes as the first Vanquish procedure performed in routine commercial practice on the U.S. East Coast. The procedure was carried out by Dr. Robert Given at Urology Of Virginia, in collaboration with Chesapeake Regional Surgery Center, and is presented as a milestone in broader adoption.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post describes Vanquish as an FDA-cleared system developed by Francis Medical to ablate prostate tissue using high-energy sterile water vapor via a transurethral approach. By emphasizing routine commercial use and expanding access, the update suggests early commercial traction that could support future revenue growth and strengthen the company’s positioning in the minimally invasive prostate treatment segment.
For investors, the reported momentum in physician uptake may indicate progress in converting clinical development into recurring commercial procedures. If adoption continues across additional centers, Francis Medical could improve its competitive profile against established prostate treatment modalities and potentially enhance its attractiveness to strategic partners or acquirers in urology and medtech.